The effectiveness of inferior vena cava filter (IVCF) insertion in reducing venous thromboembolism (VTE)-associated morbidity and mortality is uncertain.¹ Nevertheless, IVCF placement rates in the United States have been rapidly increasing and are 25-fold higher than in Europe.¹ Prompted by the report by Nicholson et al² in this journal of high prevalence of fracture and embolization, with potentially life-threatening sequelae of the Bard Recovery and Bard G2 IVC filters, the US Food and Drug Administration (FDA) issued a device safety warning on August 9, 2010, after reviewing 921 adverse events (ie, device migration, fracture, thrombosis) reported over a 5-year period.³ We sought to assess the nationwide utilization rates of IVCF placement in the United States and the impact of this FDA advisory. We also evaluated VTE-related hospitalization rates during the same period to determine whether any change in IVCF utilization could be accounted for by changes in VTE-related hospitalizations. Temple University waived the requirement for institutional review board approval.

下腔静脉滤器（IVCF）插入在减少静脉血栓栓塞（VTE）相关的发病率和死亡率方面的有效性尚不确定。¹然而，美国的IVCF安置率一直在迅速增长，比欧洲高25倍。¹根据Nicholson等人的报告²在骨折和栓塞的高患病率报告中，加上Bard Recovery和Bard G2 IVC过滤器可能危及生命的后遗症，美国食品药品监督管理局（FDA）发布了设备安全性声明在审查了过去5年内报告的921次不良事件（例如器械迁移，骨折，血栓形成）后，于2010年8月9日发出警告。³我们试图评估美国IVCF放置的全国利用率以及该FDA咨询的影响。我们还评估了同期VTE相关的住院率，以确定IVTE相关住院的变化是否可以解释IVCF利用率的任何变化。天普大学放弃了机构审查委员会批准的要求。